Summary: Background: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM). including acute myeloid leukaemia and myelodysplastic syndrome. Later. meta-analysis suggested the link to be secondary to lenalidomide in combination with melphalan. https://www.roneverhart.com/Jouer-Soft-Focus-Hydrate-Set-Powder/